BR9915394A - Preparação terapêutica antifúngica para unhas - Google Patents

Preparação terapêutica antifúngica para unhas

Info

Publication number
BR9915394A
BR9915394A BR9915394-7A BR9915394A BR9915394A BR 9915394 A BR9915394 A BR 9915394A BR 9915394 A BR9915394 A BR 9915394A BR 9915394 A BR9915394 A BR 9915394A
Authority
BR
Brazil
Prior art keywords
dmso
solution
miconazole
ibuprofen
polyglycol
Prior art date
Application number
BR9915394-7A
Other languages
English (en)
Inventor
Stanley Forrest Reeves
Original Assignee
Astan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astan Inc filed Critical Astan Inc
Publication of BR9915394A publication Critical patent/BR9915394A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PREPARAçãO TERAPêUTICA ANTIFúNGICA PARA UNHAS". Uma solução terapêutica e procedimento de aplicação para curar infecções de fungos de unhas ou Onicomicose compreendendo uma combinação de um agente antifúngico com DMSO em uma solução anidra de Poliglicol e incluindo um agente anti-inflamatório secundário. O DMOS atua como um veiculo de entrega de modo que agentes ativos antifúngicos tais como Miconazola em combinação com um composto anti-inflamatório tal como ibuprofeno podem ser entregues diretamente às áreas infectadas por fungos debaixo e em torno da unha. O DMSO, Miconazola e ibuprofeno são dissolvidos em uma solução viscosa de Poliglicol de modo que os ingredientes combinados podem ser aplicados diretamente às unhas afetadas com mais penetração. A solução terapêutica é formulada pela dissolução de Miconazola no Poliglicol com calor e pela dissolução de ibuprofeno em DMSO com calor adicional para formar uma segunda solução e em seguida combinando as duas soluções para formar a solução terapêutica. Aplicações repetidas da solução resultante sobre unhas infectadas por Onicomicose durante 4-6 semanas produzem taxas de resultados satisfatórios tão elevados como 85-90% sem aumentar a terapia com drogas sistêmicas. Antecipa-se que muitas versões da solução terapêutica não necessitam de prescrição.
BR9915394-7A 1998-11-16 1999-11-15 Preparação terapêutica antifúngica para unhas BR9915394A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/193,073 US6159977A (en) 1998-11-16 1998-11-16 Therapeutic anti-fungal nail preparation
PCT/US1999/027053 WO2000028821A1 (en) 1998-11-16 1999-11-15 Therapeutic anti-fungal nail preparation

Publications (1)

Publication Number Publication Date
BR9915394A true BR9915394A (pt) 2002-03-05

Family

ID=22712177

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915394-7A BR9915394A (pt) 1998-11-16 1999-11-15 Preparação terapêutica antifúngica para unhas

Country Status (12)

Country Link
US (2) US6159977A (pt)
EP (1) EP1130964B1 (pt)
JP (1) JP2003535020A (pt)
CN (1) CN1181738C (pt)
AT (1) ATE309032T1 (pt)
AU (1) AU771851B2 (pt)
BR (1) BR9915394A (pt)
CA (1) CA2351536C (pt)
DE (1) DE69928278T2 (pt)
IL (1) IL143156A (pt)
MX (1) MXPA01004908A (pt)
WO (1) WO2000028821A1 (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605751B1 (en) 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US6541517B1 (en) * 1999-09-03 2003-04-01 Donald M. Murphy Treatment of skin disorders
US8679523B2 (en) 1999-12-30 2014-03-25 Kimberly-Clark Worldwide, Inc. Oxygen-delivery closed cell foam matrix for wound treatment
US8257688B2 (en) * 2000-03-27 2012-09-04 Taro Pharmaceuticals Industries Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues
US7074392B1 (en) * 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
US6878365B2 (en) * 2001-03-10 2005-04-12 James Edward Brehove Topical application for treating toenail fungus
GB0108082D0 (en) * 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
JP2010209109A (ja) * 2001-06-25 2010-09-24 Regents Of The Univ Of Michigan 抗微生物ナノエマルジョンの組成物および方法
AU2002364893A1 (en) * 2001-10-22 2003-06-17 University Of Mississippi Delivery of medicaments to the nail
US20030144625A1 (en) * 2002-01-28 2003-07-31 Garry Sherman Method and apparatus for the treatment of infections of the nail matrix and nail plate
CN1678277B (zh) 2002-07-29 2010-05-05 艾克里麦德公司 治疗皮肤病的方法和组合物
US6921529B2 (en) * 2002-07-29 2005-07-26 Joseph C. Maley Treatment modality and method for fungal nail infection
US7374772B2 (en) * 2002-11-07 2008-05-20 Bommarito Alexander A Topical antifungal treatment
US20040126343A1 (en) * 2002-12-26 2004-07-01 Garshowitz Solomon David Nail drug delivery
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
US10251392B2 (en) 2004-07-30 2019-04-09 Avent, Inc. Antimicrobial devices and compositions
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
EP1778010B1 (en) 2004-07-30 2014-06-04 Kimberly-Clark Worldwide, Inc. Antimicrobial silver compositions
WO2006034249A2 (en) 2004-09-20 2006-03-30 Acrymed, Inc. Antimicrobial amorphous compositions
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
CA2590136A1 (en) * 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
US20060251593A1 (en) * 2005-04-07 2006-11-09 Work By Docs, Inc. Colored nail enamel treatment
JP2010279384A (ja) * 2005-08-31 2010-12-16 Pola Pharma Inc 抗真菌剤
US20090215888A1 (en) * 2006-03-02 2009-08-27 Singh Jagat Topical nail formulation
WO2007127236A2 (en) 2006-04-28 2007-11-08 Acrymed, Inc. Antimicrobial site dressings
PT2018164T (pt) 2006-05-12 2017-06-12 Christian Noe Utilização de preparações combinadas que compreendem antimicóticos
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2008156798A1 (en) * 2007-06-19 2008-12-24 Prugen, Inc. Drug combination for the treatment of skin disorders
US20110082118A1 (en) * 2007-06-19 2011-04-07 Bhiku Patel Onychomycosis Treatment Delivery System
US20110076261A1 (en) * 2007-06-19 2011-03-31 Bhiku Patel Antifungal Drug Delivery System
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US9320921B2 (en) * 2008-12-22 2016-04-26 Karen C. Swenholt Nail fungus treatment and composition
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CN102395274B (zh) * 2009-02-13 2014-03-12 托派卡医药股份有限公司 抗真菌制剂
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
GB0907553D0 (en) 2009-05-01 2009-06-10 Insense Ltd Treatment of human or animal body surface infection
US20100292333A1 (en) * 2009-05-15 2010-11-18 bioCEPTA Corporation Compositions suitable for the topical treatment of fungal infections of the skin and nails
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
SI23311A (sl) * 2010-03-19 2011-09-30 Kemijski inštitut Farmacevtska kombinacija acetilsalicilne kisline in protiglivne substance za uničevanje ali inhibicijo rasti in replikacije gliv
ES2369101B2 (es) 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012126899A2 (en) * 2011-03-18 2012-09-27 Katholieke Universiteit Leuven Ku Leuven Research & Development Inhibition and treatment of biofilms
CA2835684C (en) * 2011-05-11 2019-10-08 Alc Therapeutics, Llc Antifungal compositions for the treatment of skin and nails
CA2834855C (en) 2011-05-25 2020-12-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
ES2617968T3 (es) 2011-05-25 2017-06-20 Novaliq Gmbh Composición farmacéutica para la administración a uñas
MX361681B (es) 2012-01-23 2018-12-13 Novaliq Gmbh Composiciones de proteína estabilizadas basadas en alcanos semifluorados.
JP6122035B2 (ja) 2012-02-17 2017-04-26 ヴェローチェ・バイオファーマ・エルエルシー 皮膚および爪の治療のための抗真菌組成物
CA2775393C (en) * 2012-05-02 2014-04-29 Samy Saad Topical non-aqueous pharmaceutical formulations
ES2974663T3 (es) 2012-09-12 2024-07-01 Novaliq Gmbh Alcanos semifluorados para uso en la solubilización de meibomio
CA2883003C (en) 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
CA2904703A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
CA2918419C (en) 2013-07-23 2022-05-03 Novaliq Gmbh Stabilized antibody compositions
GB2518826A (en) * 2013-09-27 2015-04-08 Thanasis Athanasiou Composition
EP2952208A1 (en) 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
SG11201703184SA (en) 2014-10-21 2017-05-30 Hexima Ltd A method of treatment
CA2973725A1 (en) 2015-01-20 2016-07-28 Veloce Biopharma Llc Novel iodophor composition and methods of use
WO2017044458A1 (en) * 2015-09-08 2017-03-16 The University Of Toledo Treatment of raynaud's phenomenon by inhibition of transient receptor potential melastatin-8 (trpm-8)
DK3355990T3 (da) 2015-09-30 2019-09-16 Novaliq Gmbh Semifluorinerede forbindelser og disses sammensætninger
AU2016329261B2 (en) 2015-09-30 2020-05-07 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
US10206962B1 (en) 2016-08-08 2019-02-19 Marlinz Pharma, LLC Method for treating fungal infections in nails
US10543276B2 (en) 2016-08-08 2020-01-28 Marlinz Pharma, LLC Topical compositions
MX2019003363A (es) 2016-09-22 2019-10-02 Novaliq Gmbh Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
WO2018117125A1 (ja) * 2016-12-19 2018-06-28 富士フイルム株式会社 経皮製剤
US20210212994A1 (en) * 2017-02-28 2021-07-15 Temple University-Of The Commonwealth System Of Higher Education Novel Econazole Nitrate Medical Patch and Methods of Use Thereof
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP2020535156A (ja) 2017-09-27 2020-12-03 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
JP7353292B2 (ja) 2018-03-02 2023-09-29 ノバリック ゲーエムベーハー ネビボロールを含む医薬組成物
US12115139B2 (en) 2018-08-15 2024-10-15 Todd Alan Weinfield Treatment methods and processes for an infected nail
US12029757B2 (en) 2018-09-27 2024-07-09 Dermaliq Therapeutics, Inc. Lipid barrier repair
ES2950878T3 (es) 2018-09-27 2023-10-16 Dermaliq Therapeutics Inc Formulación de protección solar de uso tópico
JP7500550B2 (ja) 2018-10-12 2024-06-17 ノバリック ゲーエムベーハー 乾性眼疾患の治療のための眼科用組成物
JP7563877B2 (ja) * 2018-12-14 2024-10-08 ロート製薬株式会社 爪及び爪周り用医薬組成物
JP7563878B2 (ja) * 2018-12-14 2024-10-08 ロート製薬株式会社 爪及び爪周り用医薬組成物
CN110537545A (zh) * 2019-09-12 2019-12-06 青岛农业大学 噻康唑在制备用于防治植物病原菌的杀菌剂中的应用
ES2976036A1 (es) * 2024-03-06 2024-07-22 Univ Madrid Complutense Potenciación de la acumulación intraungueal de principios activos

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048486B2 (ja) * 1976-01-01 1985-10-28 木場 常義 抗リウマチ剤
GB2105990B (en) * 1981-08-27 1985-06-19 Nitto Electric Ind Co Adhesive skin patches
US4608249A (en) * 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
CA1236029A (en) * 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
DE3520098A1 (de) * 1985-06-05 1986-12-11 Bayer Ag, 5090 Leverkusen Azolderivate enthaltende formulierungen sowie ihre verwendung zur atraumatischen nagelentfernung
EP0270316A3 (en) * 1986-12-04 1989-12-06 Pfizer Inc. Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne
JP2797401B2 (ja) * 1989-04-19 1998-09-17 日産化学工業株式会社 爪用抗真菌剤組成物
US4927641A (en) * 1989-05-23 1990-05-22 Knight Gerald L Veterinary liniment and method
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
FR2673537B1 (fr) * 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
JP3259972B2 (ja) * 1991-11-29 2002-02-25 ゼリア新薬工業株式会社 トルナフタート含有抗真菌剤
DK0616517T3 (da) * 1991-12-12 1997-10-27 Lohmann Therapie Syst Lts Selvklæbende laminat til tå- og fingernegle.
JPH07506367A (ja) * 1992-05-05 1995-07-13 ザ、プロクター、エンド、ギャンブル、カンパニー アクネ治療組成物
GB2275191B (en) * 1993-02-10 1996-11-27 Donald John Dear Use of antifungal compounds in the treatment of skin disorders
IL105600A (en) * 1993-05-04 1999-12-31 Allon Blank Pharmaceutical and cosmetic compositions with increased rate of transdermal penetration and antioxidation protection against degradation containing derivatives of thioglycolic and mercaptopropionic acids some such novel compounds and their use
DE4337945A1 (de) * 1993-11-06 1995-05-11 Labtec Gmbh Pflaster zur Behandlung von Nagelmykosen
IT1265001B1 (it) * 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico

Also Published As

Publication number Publication date
ATE309032T1 (de) 2005-11-15
MXPA01004908A (es) 2003-03-10
IL143156A0 (en) 2002-04-21
IL143156A (en) 2005-11-20
DE69928278D1 (de) 2005-12-15
EP1130964A1 (en) 2001-09-12
CN1359262A (zh) 2002-07-17
CA2351536C (en) 2007-08-07
AU1725700A (en) 2000-06-05
EP1130964A4 (en) 2002-06-19
WO2000028821A1 (en) 2000-05-25
JP2003535020A (ja) 2003-11-25
CN1181738C (zh) 2004-12-29
CA2351536A1 (en) 2000-05-25
DE69928278T2 (de) 2006-06-14
AU771851B2 (en) 2004-04-01
EP1130964B1 (en) 2005-11-09
US6159977A (en) 2000-12-12
US6391879B1 (en) 2002-05-21

Similar Documents

Publication Publication Date Title
BR9915394A (pt) Preparação terapêutica antifúngica para unhas
EP1138314A3 (en) Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues
EP1401421B1 (en) Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
CY1107925T1 (el) Διαλυμα για εφαρμογη στα νυχια
DK302782A (da) Anvendelse af eucalypol til at foroege et praeparats optagelse gennem huden
HK1083009A1 (en) Topical drug delivery using phosphatidylcholine
DK0971705T3 (da) Lægemiddelformuleringer til hormonerstatningsterapi til lokal påföring på huden
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
DK0892638T3 (da) Liposombaseret, topisk vitamin D-præparat
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
MXPA04000654A (es) Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
WO2006091719A3 (en) Compositions and methods enhancing transdermal delivery of drugs and biologics
IE810489L (en) Composition for topical application
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
BR9612316A (pt) Agente para profilaxia e tratamento de complicações diabéticas
WO2002055022A3 (en) Active metabolite of antifungal compound
DE60217292D1 (de) Veterinärmedizinische dermatologische zusammensetzung
US12115139B2 (en) Treatment methods and processes for an infected nail
MX9301537A (es) Composicion de resina de intercambio de iones.
Fukuda Diversified treatments of tinea unguium

Legal Events

Date Code Title Description
TE Change of address
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 10 (VIII) E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.